Marliese Alexander
Overview
Explore the profile of Marliese Alexander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Roberts H, Solomon B, Harden S, Lingaratnam S, Alexander M
Clin Lung Cancer
. 2024 May;
25(5):e211-e220.e1.
PMID: 38772809
Background: 30-day mortality after systemic anti-cancer therapy (SACT) has been suggested as a quality indicator primarily for measuring use of chemotherapy towards the end of life. Utility across different cancer...
12.
Fantoni A, Warburton L, Solomon B, Alexander M, Maddula M, Brown L, et al.
Clin Lung Cancer
. 2024 May;
25(5):449-459.
PMID: 38705835
Background: Seminal trials with first-line pembrolizumab for metastatic non-small cell lung cancer (NSCLC) mandated a maximum two-years treatment. We describe real-world outcomes of a multi-site Australian cohort of patients who...
13.
Wallace N, Alexander M, Xie J, Ball D, Hegi-Johnson F, Plumridge N, et al.
Lung Cancer
. 2024 Mar;
190:107531.
PMID: 38513538
Introduction: Smoking is a risk factor for the development of lung cancer and reduces life expectancy within the general population. Retrospective studies suggest that non-smokers have better outcomes after treatment...
14.
Brown L, Khou V, Brown C, Alexander M, Jayamanne D, Wei J, et al.
Front Oncol
. 2024 Feb;
14:1305720.
PMID: 38406805
Introduction: Brain metastases commonly occur in patients with non-small cell lung cancer (NSCLC). Standard first-line treatment for NSCLC, without an EGFR, ALK or ROS1 mutation, is either chemoimmunotherapy or anti-PD-1...
15.
Alexander M, ROGERs J, Parakh S, Mitchell P, Clay T, Kao S, et al.
Intern Med J
. 2024 Feb;
54(7):1087-1096.
PMID: 38369719
Background And Aims: Lurbinectedin is a novel oncogenic transcription inhibitor active in several cancers, including small cell lung cancer (SCLC). We aimed to describe the first Australian experience of the...
16.
Alexander M, Collins I, Abraham P, Underhill C, Harris S, Torres J, et al.
Intern Med J
. 2023 Dec;
53(12):2346-2349.
PMID: 38130050
This cost analysis, from a societal perspective, compared the cost difference of a networked teletrial model (NTTM) with four regional hubs versus conventional trial operation at a single metropolitan specialist...
17.
McNamee N, Harvey C, Gray L, Khoo T, Lingam L, Zhang B, et al.
J Thorac Oncol
. 2023 Nov;
19(4):636-642.
PMID: 38036250
Background: Australia has one of the highest rates of asbestos-associated diseases. Mesothelioma remains an area of unmet need with a 5-year overall survival of 10%. First-line immunotherapy with ipilimumab and...
18.
Moore C, Lazarakis S, Stenta T, Alexander M, Nguyen R, Elliott D, et al.
Pharmacol Res Perspect
. 2023 Nov;
11(6):e01150.
PMID: 38013228
Pharmacogenomics remains underutilized in clinical practice, despite the existence of internationally recognized, evidence-based guidelines. This systematic review aims to understand enablers and barriers to pharmacogenomics implementation in pediatric oncology by...
19.
Soon J, To Y, Alexander M, Trapani K, Ascierto P, Athan S, et al.
J Cancer Policy
. 2023 Nov;
38:100441.
PMID: 38008488
Background: Horizon scanning (HS) is the systematic identification of emerging therapies to inform policy and decision-makers. We developed an agile and tailored HS methodology that combined multi-criteria decision analysis weighting...
20.
Lim C, Bozkurt A, Chen Z, Hird A, Wickens J, Lazarakis S, et al.
Clin Transl Sci
. 2023 Nov;
16(12):2467-2482.
PMID: 37991131
Clinical implementation of pharmacogenomic (PGx)-guided prescribing in oncology lags behind research evidence generation. We aimed to identify healthcare professionals' (HCPs) and consumers' knowledge, attitudes, perspectives, and education needs to inform...